当前位置: 首页 >> 检索结果
共有 7000 条符合本次的查询结果, 用时 3.4100996 秒

6061. Manometrically jackhammer esophagus with fluoroscopically/endoscopically distal esophageal spasm: a case report.

作者: Apichet Sirinawasatien.;Pallop Sakulthongthawin.
来源: BMC Gastroenterol. 2021年21卷1期222页
Jackhammer esophagus is a rare esophageal motility disorder that can result in dysphagia, chest pain, and gastro-esophageal reflux symptoms. High-resolution manometry is the gold standard for diagnosis, while corkscrew esophagus on upper gastrointestinal endoscopy is an uncommon manifestation.

6062. Association of meat consumption with NAFLD risk and liver-related biochemical indexes in older Chinese: a cross-sectional study.

作者: Hewei Peng.;Xiaoxu Xie.;Xinting Pan.;Jing Zheng.;Yidan Zeng.;Xiaoling Cai.;Zhijian Hu.;Xian-E Peng.
来源: BMC Gastroenterol. 2021年21卷1期221页
Non-alcohol fatty liver disease (NAFLD) is the most common liver disease and an unhealthy lifestyle can lead to an increased risk of NAFLD. The present study aims to evaluate the association of meat consumption with NAFLD risk and liver-related biochemical indexes in middle-aged and elderly Chinese.

6063. The Colorectal Cancer Lipidome: Identification of a Robust Tumor-Specific Lipid Species Signature.

作者: Josef Ecker.;Elisa Benedetti.;Alida S D Kindt.;Marcus Höring.;Markus Perl.;Andrea Christel Machmüller.;Anna Sichler.;Johannes Plagge.;Yuting Wang.;Sebastian Zeissig.;Andrej Shevchenko.;Ralph Burkhardt.;Jan Krumsiek.;Gerhard Liebisch.;Klaus-Peter Janssen.
来源: Gastroenterology. 2021年161卷3期910-923.e19页
Lipidomic changes were causally linked to metabolic diseases, but the scenario for colorectal cancer (CRC) is less clear. We investigated the CRC lipidome for putative tumor-specific alterations through analysis of 3 independent retrospective patient cohorts from 2 clinical centers, to derive a clinically useful signature.

6064. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.

作者: Toky Ratovomanana.;Romain Cohen.;Magali Svrcek.;Florence Renaud.;Pascale Cervera.;Aurélie Siret.;Quentin Letourneur.;Olivier Buhard.;Pierre Bourgoin.;Erell Guillerm.;Coralie Dorard.;Remy Nicolle.;Mira Ayadi.;Mehdi Touat.;Franck Bielle.;Marc Sanson.;Philippe Le Rouzic.;Marie-Pierre Buisine.;Guillaume Piessen.;Ada Collura.;Jean-François Fléjou.;Aurélien de Reyniès.;Florence Coulet.;François Ghiringhelli.;Thierry André.;Vincent Jonchère.;Alex Duval.
来源: Gastroenterology. 2021年161卷3期814-826.e7页
Next-generation sequencing (NGS) was recently approved by the United States Food and Drug Administration to detect microsatellite instability (MSI) arising from defective mismatch repair (dMMR) in patients with metastatic colorectal cancer (mCRC) before treatment with immune checkpoint inhibitors (ICI). In this study, we aimed to evaluate and improve the performance of NGS to identify MSI in CRC, especially dMMR mCRC treated with ICI.

6065. Gut Microbiome Composition Is Associated with COVID-19 Disease Severity.

作者: Pooja Patel.;Jatin Roper.
来源: Gastroenterology. 2021年161卷2期722-724页

6066. Selecting the Ideal Candidate for Anti-TNF Discontinuation in Crohn's Disease, Dream or Reality?

作者: Bram Verstockt.;Nélia Abreu.;Joana Torres.
来源: Gastroenterology. 2021年161卷1期353-355页

6067. Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis.

作者: Yaw-Sen Chen.;Pei-Min Hsieh.;Hung-Yu Lin.;Chao-Ming Hung.;Gin-Ho Lo.;Yao-Chun Hsu.;I-Cheng Lu.;Chih-Yuan Lee.;Tsung-Chin Wu.;Jen-Hao Yeh.;Pojen Hsiao.;Yu-Chan Li.;Ya-Chin Wang.;Kun-Chou Hsieh.;Chih-Wen Lin.
来源: BMC Gastroenterol. 2021年21卷1期220页
The benefits of surgical resection (SR) for various Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma (HCC) remain unclear. We investigated the risk factors of overall survival (OS) and survival benefits of SR over nonsurgical treatments in patients with HCC of various BCLC stages.

6068. Development of AGA's Policy Agenda During the COVID-19 Pandemic.

作者: Simon C Mathews.;Yamini Natarajan.;M Anthony Sofia.;Amit Patel.;Dawn Francis.;Sarah Streett.;Shazia Mehmood Siddique.; .
来源: Gastroenterology. 2021年161卷3期765-769页

6069. New Drugs on the Horizon for Functional and Motility Gastrointestinal Disorders.

作者: Michael Camilleri.
来源: Gastroenterology. 2021年161卷3期761-764页

6070. Nonselective Beta-Blockers in Compensated Cirrhosis: Preventing Variceal Hemorrhage or Preventing Decompensation?

作者: Guadalupe Garcia-Tsao.;Juan G Abraldes.
来源: Gastroenterology. 2021年161卷3期770-773页

6071. Hopes and Hypes for Artificial Intelligence in Colorectal Cancer Screening.

作者: Yuichi Mori.;Michael Bretthauer.;Mette Kalager.
来源: Gastroenterology. 2021年161卷3期774-777页

6072. Fatigue, sarcopenia, and frailty in older adults with inflammatory bowel disease.

作者: Federica Bellone.;Alberto Sardella.;Marco Muscianisi.;Giorgio Basile.
来源: Minerva Gastroenterol (Torino). 2024年70卷1期79-88页
Inflammatory bowel diseases (IBDs) are characterized by a multifactorial clinical picture, in which age-related physical, functional and psychological symptoms may coexist. The accurate evaluation and identification of such symptomatology acquires considerable importance in the context of older adults, since those core factors typical of IBD may also expose older patients to an increased risk for age-related negative outcomes, such as frailty and disability. The purpose of the present review was to provide an updated overview on the evaluation and management of IBD in the elderly population, with regard to fatigue, sarcopenia, and frailty. The assessment of fatigue might contribute to the identification of early symptoms of IBD, such as pain and mood disorders, which should be treated timely to offer elderly patient a better quality of life. Similarly, an accurate evaluation of sarcopenia might represent a useful Prognostic Index to identify those patients at risk of developing physical frailty. Frailty in IBD should be evaluated not only in relation to the occurrence of negative outcomes, but also should be considered itself as an outcome itself in IBD. A recommendation for future research on this topic might be the implementation of randomized trials, which include older adults and evaluate fatigue, sarcopenia, and frailty. Similarly, the development of tailored intervention programs, based on both physical and psychological outcomes, with the purpose of improving patients' adaptation to the disease, and monitoring the evolution of symptoms and the response to therapies over time, should be encouraged.

6073. Role of endoscopic ultrasonography in the management of peripancreatic collections.

作者: Cecilia Binda.;Chiara Coluccio.;Monica Sbrancia.;Carlo Fabbri.
来源: Minerva Gastroenterol (Torino). 2022年68卷2期162-176页
Pancreatic fluid collections are surrounded by a wall of granulation tissue and may contain necrotic debris. They occur following a severe acute pancreatitis and most of the cases resolve spontaneously after several weeks. However, their management may lead to a very hard-to-treat condition, requiring a multidisciplinary approach. During the last decades we assisted to a change of paradigm involving Endoscopic Ultrasonography, from a pure diagnostic technique to an interventional-therapeutic one, allowing an effective, safe and less invasive approach than other existing treatment standards, historically consisting of surgical and percutaneous drainage. Treatment of pancreatic fluid collections is indicated if they become infected or symptomatic. Over the past years, exponential developments were done in interventional endoscopic approach, making it the first line suggested modality. The use of endoscopic ultrasound allows assessment of the collection, even when it is not directly bulging on gastrointestinal wall, creation of an internal fistulous tract, checking for surrounding vessels with the use of Doppler, and deployment of a stent avoiding the discomfort of external tubes. Several types of stent have been used for endoscopic drainage: plastic double pigtail stents, fully covered self-expanding metal stents and, more recently, lumen apposing metal stents, which are considered revolutionary because of their two-side flanges and wide and short internal channel, a new design that made easier direct endoscopic necrosectomy. This review aims to go through currently available literature on the diagnostic and therapeutic role of endoscopic ultrasonography to handle pancreatic fluid collections.

6074. Schistosoma mansoni-related periportal fibrosis; can we use APRI and PSDR levels in the real-time selection of patients for targeted endoscopy in a resource-limited setting? A case-control study.

作者: Daniel W Gunda.;Elizabeth F Mtui.;Paulina M Manyiri.;David C Majinge.;Semvua B Kilonzo.;Humphrey D Mazigo.;Benson R Kidenya.
来源: BMC Gastroenterol. 2021年21卷1期219页
Schistosoma mansoni related hepatic fibrosis is usually associated with hemodynamic alteration with increased mortality due to bleeding varices. The diagnosis of varices before bleeding imposes a big challenge in resource-limited countries using endoscopy. Published evidence on the utility of non-invasive clinical tools in predicting the presence of varices among patients with S. mansoni related periportal fibrosis is still inadequate including Aspartate to platelet ratio index (APRI) and Platelet to splenic diameter ratio (PSDR) levels. This study describes the determinants of portal varices and assesses the potential utility of the APRI and PSDR level in the discrimination of portal varices among patients with S. mansoni related periportal fibrosis (PPF).

6075. Risk factors associated with functional dyspepsia in Chinese children: a cross-sectional study.

作者: Zhongcao Wei.;Xing Yang.;Xin Xing.;Lei Dong.;Jinhai Wang.;Bin Qin.
来源: BMC Gastroenterol. 2021年21卷1期218页
There is no study assessing the risk factors associated with functional dyspepsia (FD) in Chinese children based on the Rome IV criteria.

6076. Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma.

作者: Nguyen Van Thai.;Nguyen Tien Thinh.;Thai Doan Ky.;Mai Hong Bang.;Dinh Truong Giang.;Le Ngoc Ha.;Mai Hong Son.;Dao Duc Tien.;Hyun Woong Lee.
来源: BMC Gastroenterol. 2021年21卷1期216页
This retrospective analysis was undertaken to evaluate the efficiency of SIRT with Y-90 microspheres and determined prognostic factors affecting patients with unresectable HCC.

6077. Prevalence of constipation in adults with obesity class II and III and associated factors.

作者: Erika Aparecida Silveira.;Annelisa Silva E Alves de Carvalho Santos.;Jessivane Nascimento Ribeiro.;Matias Noll.;Ana Paula Dos Santos Rodrigues.;Cesar de Oliveira.
来源: BMC Gastroenterol. 2021年21卷1期217页
Constipation and obesity have common risk factors. However, little is known about the occurrence of constipation in individuals with severe obesity and the associated factors.

6078. Long-term benefits of viral clearance on extrahepatic manifestations of hepatitis C virus infection: the light at the end of the tunnel?

作者: Giorgio M Saracco.
来源: Minerva Gastroenterol (Torino). 2021年67卷3期215-217页

6079. Nutraceuticals and microbiota.

作者: Luis E Díaz-Orozco.;Nahum Méndez-Sánchez.
来源: Minerva Gastroenterol (Torino). 2021年67卷4期326-338页
Nutraceuticals are defined as products isolated or purified from foods that are generally sold in medicinal or dosage forms not usually associated with food which is demonstrated to have a physiological benefit or provide protection against chronic disease. In this context, the products offered should be rigorously evaluated by international regulatory agencies. More recently, nutraceuticals have been proposed as a potential preventive and therapeutic option in the assessment of chronic diseases, mainly by altering the microbiome composition. However, the current lack of conclusive evidence supporting the "healthy" or "normal" microbiome, along with the dysbiosis concept paradigm, could be both contributing to the lack of homogeneous results. These issues may be solved in the next years with the use of emergent technologies in the individual's microbiome assessment and its fluctuations in time or related to many factors, such as nutraceuticals. Additionally, future research assessing the independent association between the dysbiosis modification and any "potential" nutraceutical product (including bioactive ingredient or chemical compound in food) is going to enlarge the currently reduced "established nutraceuticals" group. In this work we have assessed the nutraceutical's potential role as a microbiome-targeted manipulation therapy, and the gut-liver axis involved in the digestive diseases' pathogenesis and progression, including the chronic liver diseases. Moreover, microbiome targeted nutraceuticals that show consistent results might be further included in clinical research and trials in the therapeutic assessment of chronic diseases. Finally, the indication of these quality microbiome-targeted nutraceuticals will undoubtedly carry health benefits for individuals.

6080. Probiotics and gut health.

作者: Emidio Scarpellini.;Martina Basilico.;Emanuele Rinninella.;Florencia Carbone.;Jolien Schol.;Carlo Rasetti.;Ludovico Abenavoli.;Pierangelo Santori.
来源: Minerva Gastroenterol (Torino). 2021年67卷4期314-325页
Gut microbiota is a complex ecosystem of bacteria, viruses, archea, protozoa and yeasts in our intestine. It has several functions which maintain human body equilibrium. Microbial "dysbiosis" can be responsible for several gastrointestinal diseases. To build a narrative review we performed a Pubmed, Medline, Embase search for English language papers, reviews, meta-analyses, case series, and randomized controlled trials (RCTs) by keywords and their associations. Gut microbiota is altered in several gastrointestinal diseases with very different pathophysiology. They range from multifactorial diseases such as irritable bowel syndrome (IBS), nonalcoholic fatty liver disease (NAFLD) and gastric and colorectal cancers, immune-mediated such as celiac disease, inflammatory bowel diseases (IBD), and antibiotic-related such as clostridium difficile infection (CDI). Microbial dysbiosis remodulation by probiotics is feasible and safe in some of them. Gut microbial dysbiosis is statistically associated with several gastrointestinal diseases, affecting their pathophysiology. Its reverse by probiotics has some promising evidence of efficacy.
共有 7000 条符合本次的查询结果, 用时 3.4100996 秒